Oxcia employs a Chief Medical Officer (CMO)

Oxcia is happy to announce that MedDr and Ass.Prof. Cecilia Ahlin has accepted the CMO position. With her extensive experience as medical oncologist and gynecology oncologist (still clinically active), clinical assessor for Medical Product Agency (MPA), and from previous positions as associate Director and Medical Head within the pharma industry, she will be a strong asset to the company. We are very pleased to welcome her onboard to Oxcia!

Latest news

  • Tredje kvartalet (juli-september 2022) Rörelseresultatet uppgick till -10 927 043 (-3 573 590) SEK. Periodens resultat uppgick till -10 927 043 (-3 578 876) SEK. Kassaflödet från den löpande verksamheten uppgick till -4 612 924 (-2 749 079) SEK. Resultat per aktie före utspädning uppgick till -0,51… Continue reading Oxcia AB publicerar sin delårsrapport för tredje kvartalet 2022

    Read more

  • En ny studie, ”Pharmacological OGG1 inhibition decreases murine allergic airway inflammation” (fritt översatt: Farmakologisk OGG1-hämning minskar allergisk luftvägsinflammation i sjukdomsmodeller), publicerades den 17 oktober i Frontiers in Pharmacology, Respiratory pharmacology ( DOI 10.3389/fphar.2022.999180, Tanner L, Bergwik J, Bhongir RKV, Pan L C, Wallner O, Kalderén C, Helleday T, Boldogh I, Adner M och Egesten A) och visar att Oxcias läkemedelskandidat OXC-201 (TH5487) kan vara en lovande behandling för allergisk astma.

    Read more

  • A new study, Pharmacological OGG1 inhibition decreases murine allergic airway inflammation, was published 17[th] of October in Respiratory pharmacology, Frontiers in Pharmacology, (DOI 10.3389/fphar.2022.999180, Tanner L, Bergwik J, Bhongir RKV, Pan L, Dong C, Wallner O, Kalderén C, Helleday T, Boldogh I, Adner M and Egesten A) and demonstrates that Oxcia’s potential clinical candidate OXC-201 (TH5487) may be a promising treatment for allergic asthma.

    Read more